The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
Sara Elena RebuzziAlessio SignoriGiuseppe Luigi BannaAnnalice GandiniGiuseppe FornariniAlessandra DamassiMarco MaruzzoUgo De GiorgiUmberto BassoSilvia ChiellinoLuca GalliPaolo Andrea ZucaliEmanuela FantinelEmanuele NaglieriGiuseppe ProcopioMichele MilellaFrancesco BoccardoLucia FratinoStefania PipitoneRiccardo RicottaStefano PanniVeronica MollicaMariella SorarùMatteo SantoniAlessio CortelliniVeronica PratiHector Josè Soto ParraDaniele SantiniFrancesco AtzoriMarilena Di NapoliOrazio CaffoMarco MessinaFranco MorelliGiuseppe PratiFranco NolèFrancesca VignaniAlessia CavoGiandomenico RovielloPasquale RescignoSebastiano ButiPublished in: Journal of translational medicine (2022)
Our study suggests an overall positive impact of the previous nephrectomy on the outcome of pretreated mRCC patients receiving immunotherapy. The clinical relevance of cytoreductive nephrectomy, optimal timing and patient selection deserves further investigation, especially for patients with Meet-URO scores of 1 to 3, who are the once deriving benefit in our analyses. However, that benefit is not evident for IMDC poor-risk patients (including the Meet-URO score groups 4 and 5) and a subgroup of IMDC intermediate-risk patients defined as group 4 by the Meet-URO score.